Today "172
" News and Relevant News on "172
" as Parts
Keyword: 172
Century Park Law Group - centuryparklawgroup.com
News Center
Alarming superbug from deadly eyedrop outbreak has spread to dogs
It's unclear how the dogs became infected with the same strain in the eyedrops.Europeas ambitious satellite Internet project appears to be running into trouble
The devil, as always, is in the details.Daily Telescope: The Horsehead Nebula as weave never seen it before
Webb delivers with a new look on an iconic classic. Two giants in the satellite telecom industry join forces to counter Starlink
SES is buying Intelsat, the world's first commercial satellite operator, for $3.1 billion.DEA to reclassify marijuana as a lower-risk drug, reports say
Marijuana to move from Schedule 1, the most dangerous drug group, to Schedule 3.Researchers make a plastic that includes bacteria that can digest it
Bacterial spores strengthen the plastic, then revive to digest it in landfills.New space company seeks to solve orbital mobility with high delta-v spacecraft
"If weare going to have a true space economy, that means logistics and supply services."NASA lays out how SpaceX will refuel Starships in low-Earth orbit
"The fundamental flow mechanism is the pressure delta across the umbilical."Cats suffer H5N1 brain infections, blindness, death after drinking raw milk
Mammal-to-mammal transmission raises new concerns about the virus's ability to spread.Swimming and spinning aquatic spiders use slick survival strategies
Some make nests inside seashells, others tote bubbles of air on their backs. Why Germany ditched nuclear before coalaand why it wonat go back
The past year has seen record renewable power production nationwide.USas power grid continues to lower emissionsaeverything else, not so much
Excluding one pandemic year, emissions are lower than they've been since the 1980s.20% of grocery store milk has traces of bird flu, suggesting wider outbreak
The milk is still considered safe, but disease experts are alarmed by the prevalence.Lost opportunity: We couldave started fighting climate change in 1971
President Nixon's science advisors recommended building global CO2 monitoring network.Rocket Report: SLS workforce cuts; New Glenn launch to launch in the early fall
"This is a vital component in our preparations for launch."Russia stands alone in vetoing UN resolution on nuclear weapons in space
"The United States assesses that Russia is developing a new satellite carrying a nuclear device."Three women contract HIV from dirty avampire facialsa at unlicensed spa
Five patients with links to the spa had viral genetic sequences that closely matched.Deciphered Herculaneum papyrus reveals precise burial place of Plato
Various imaging methods comprised a kind of "bionic eye" to examine charred scroll.EPA issues four rules limiting pollution from fossil fuel power plants
Coal to be hit hard, natural gas plants will have to capture carbon emissions.If Starship is real, weare going to need big cargo movers on the Moon and Mars
"I left SpaceX knowing the width of the Starship door."Cholesterol activates signaling pathway that promotes cancer
Everyone knows that cholesterol, at least the bad kind, can cause heart disease and hardening of the arteries. Now, researchers at the University of Illinois at Chicago describe a new role for cholesterol in the activation of a cellular signaling pathway that has been linked to cancer. The finding is reported in Nature Communications. Cells employ thousands of signaling pathways to conduct their functions. Canonical Wnt signaling is a pathway that promotes cell growth and division and is most active in embryonic cells during development. Overactivity of this signaling pathway in mature cells is thought to be a major driver in the development of cancer. âOur research points to a new regulatory role for cholesterol, and also presents an exciting new therapeutic target for suppressing canonical Wnt signaling to treat or prevent cancer,â said Wonhwa Cho, professor of chemistry at UIC and principal investigator of the research.Cholesterol levels vary by season, get worse in colder months
Cholesterol levels fluctuate based on the time of year with more unfavorable lipid profiles seen in the colder months, a trend that may be driven by related behavior changes, according to research to be presented at the American College of Cardiologyâs 63rd Annual Scientific Session. While previous studies have shown that heart attacks and heart-related deaths increase during the winter months, researchers at Johns Hopkins Ciccarone Center for the Prevention of Heart Disease were interested in finding out whether cholesterol parameters might follow a similar pattern among a sample of 2.8 million adults - the largest study to look at seasonal lipid trends in U.S. adults to date. Abnormal cholesterol levels are a well-known cardiovascular risk factor. âIn this very large sample, we found that people tend to have worse cholesterol numbers on average during the colder months than in the warmer months - not by a very large amount, but the variation is significant,â said Parag Joshi, M.D., cardiology fellow, Johns Hopkins Hospital, and lead investigator of the study. âIt confirms findings from smaller studies and raises a lot of interesting questions, including what might be driving these [fluctuations].â Researchers caution these findings do not mean patients should have their cholesterol checked more frequently or at certain times of the year; the data instead validates a clear seasonal pattern and underscores the need to pay attention to behaviors that are critical to minimizing cardiovascular risk.Early statin therapy helps kids with inherited high cholesterol
Children with inherited high levels of cholesterol who receive cholesterol-lowering statins in their early years have a lower risk of coronary heart disease than their affected parents, according to research presented at the American Heart Associationâs Scientific Sessions 2013. Researchers evaluated the effectiveness and safety of statin treatment in 214 children with familial hypercholesterolemia (FH). The children, 8- to 18-years-old, continued to receive statins and were evaluated after 10 years. Researchers reported that at age 30, coronary heart disease survival was 100 percent in the group of young adults who received statins from childhood and 93 percent in the affected parents. âOur results suggest statin therapy initiated in childhood reduces disease and death from heart disease in patients with FH,â said Marjet Braamskamp, M.D., study co-author and a Ph.D. student at the Academic Medical Center in Amsterdam, the Netherlands. âAfter 10 years of treatment, young adult FH patients had not suffered from cardiovascular complaints.âA mother’s high cholesterol before pregnancy can be passed on to her children
What leads to high cholesterol? Your genes and lifestyle factors may not explain it all. A study presented today at the Canadian Cardiovascular Congress has connected some of the risk for high cholesterol in adults to their motherâs cholesterol levels before she even became pregnant. The key finding: if a mother had high LDL (âbadâ) cholesterol prior to a pregnancy, her children are almost five times as likely to also have high LDL cholesterol as adults. âMaternal health and exposures in the womb may be important in modifying cardiovascular disease risks for their offspring,â says author Dr. Michael Mendelson, a clinical and research fellow at Boston Childrenâs Hospital. âOne exposure that hasnât been explored well is high cholesterol in young women of childbearing age. We wanted to know: does this pose an extra risk for the child?â The study analyzed clinical and laboratory data gathered from the three generations of participants in the Framingham Heart Study (FHS). This ongoing study goes back to 1948 and led the way to identifying risk factors for cardiovascular disease.When it comes to the good cholesterol, fitness trumps weight
Thereâs no question that high levels of good cholesterol - also known as high-density lipoprotein (HDL) - seem to be protective against heart disease. Rather than depositing fat into the blood vessels the way the âbadâ cholesterol (low-density lipoprotein (LDL)) does, HDL appears to carry cholesterol away from blood vessels to the liver. From there, the liver processes it for removal from the body. However, adequate levels of HDL might not be enough. Several recent studies have suggested that many cases of heart disease occur in people with normal levels of HDL cholesterol. Consequently, some researchers believe that even if people have adequate amounts of HDL cholesterol, it might not work well. Such HDL may not fulfill this moleculeâs other important duties in the body, such as reducing inflammation and acting as an antioxidant. Because exercise has the potential to protect against heart disease in a variety of ways, Christian K. Roberts and his colleagues at UCLA tested whether HDL in men who weight trained regularly behaved in a healthier way than HDL in sedentary men. They found that the men who didnât exercise were more likely than those who weight trained to have dysfunctional HDL. Having faulty HDL was associated with numerous other risk factors for heart disease, including high triglycerides and a higher trunk fat mass. This finding held true regardless of the menâs weight, which suggests that maintaining a âhealthyâ weight isnât as important for healthy cholesterol function as being active by regularly performing strength training. The article is entitled âUntrained Young Men Have Dysfunctional HDL Compared to Strength Trained Men Irrespective of Body Weight Status.â It appears in the Articles in PresS section of Journal of Applied Physiology, published by the American Physiological Society.Unnecessary repeat cholesterol tests common: study
One-third of people with heart disease have their cholesterol levels checked more often than guidelines recommend, a new study of Veterans Affairs (VA) patients suggests. Researchers said such extra testing may be a waste of time and money if it doesnât lead to improvements in patientsâ health. The findings are âvery unsurprising,â according to Dr. Michael Johansen of The Ohio State University in Columbus, who has studied cholesterol management. He said doctors may order more tests to meet (or exceed) performance measures, and because they get paid for running a cholesterol panel.Specialized treatment helps cholesterol patients who suffer side effects from statins
Up to 15 percent of patients who take cholesterol-lowering statin medications experience muscle pain or other side effects, and many patients simply stop taking the drugs. But a Loyola University Medical Center study has found that âstatin-intolerantâ patients still can significantly reduce their cholesterol by going to a lipid clinic staffed with physicians specially trained in treating cholesterol problems. Among 22 statin-intolerant patients referred to Loyolaâs Lipid Clinic, total cholesterol dropped from 257 mg/dl to 198 mg/dl. LDL (âbadâ) cholesterol dropped from 172 mg/dl to 123 mg/dl, the study found. By comparison, in a control group of 21 statin-intolerant patients who were not referred to a lipid clinic, total cholesterol dropped by only 3 points, and LDL cholesterol dropped by only 1 point.Researchers Find New Way to Clear Cholesterol From the Blood
Researchers at the University of Michigan have identified a new potential therapeutic target for lowering cholesterol that could be an alternative or complementary therapy to statins. Scientists in the lab of David Ginsburg at the Life Sciences Institute inhibited the action of a gene responsible for transporting a protein that interferes with the ability of the liver to remove cholesterol from the blood in mice. Trapping the destructive protein where it couldnât harm receptors responsible for removing cholesterol preserved the liver cellsâ capacity to clear plasma cholesterol from the blood, but did not appear to otherwise affect the health of the mice. In the research, published April 9 in the online journal eLife, scientists found that mice with an inactive SEC24A gene could develop normally. However, their plasma cholesterol levels were reduced by 45 percent because vesicles from liver cells were not able to recruit and transport a critical regulator of blood cholesterol levels called proprotein convertase subtilisin/kexin type 9. PCSK9 is a secretory protein that destroys the liver cellsâ receptors of low-density lipoprotein- LDL, the so-called âbad cholesterolâ-and prevents the cells from removing the LDL. âInhibiting SEC24A or PCSK9 may be an alternative to statins, and could work together with statins to produce even greater effects,â said Xiao-Wei Chen of the Ginsburg lab, the first author on the paper. âAlso, they might be effective on patients who are resistant to or intolerant of statins.âCholesterol buildup links atherosclerosis and macular degeneration
A new study raises the intriguing possibility that drugs prescribed to lower cholesterol may be effective against macular degeneration, a blinding eye disease. Researchers at Washington University School of Medicine in St. Louis have found that age-related macular degeneration, the leading cause of vision loss in Americans over 50, shares a common link with atherosclerosis. Both problems have the same underlying defect: the inability to remove a buildup of fat and cholesterol. The new study is published online in the journal Cell Metabolism. Working in mice and in human cells, the researchers shed new light on how deposits of cholesterol contribute to macular degeneration and atherosclerosis and even blood vessel growth in some types of cancer.Merck CEO says jury out on raising good cholesterol
The jury is still out on the benefits of increasing âgoodâ HDL cholesterol, but the strategy remains worth pursuing, despite recent setbacks, the chief executive of said on Thursday. Confidence in the HDL thesis suffered a fresh blow last month when a major clinical trial of Merckâs Tredaptive medicine failed. That followed earlier failures with two other HDL-boosting drugs from Pfizer and Roche. The Pfizer and Roche drugs worked differently to Tredaptive, by inhibiting a protein called CETP, and Merck is also developing a key experimental product in this area. Merck CEO Ken Frazier, speaking in Davos on the sidelines of the World Economic Forum, said the U.S. drugmaker would continue to press ahead with clinical research on HDL raising, even though the scientific case so far remained inconclusive.Page took 2 seconds to load.
Home Page